Bio-Techne at Jefferies Conference: Strategic Growth Amid Challenges

Bio-Techne (TECH) presented at the Jefferies Global Healthcare Conference 2025, projecting low single-digit growth for Q4, with pharma growth moderating to mid-single digits amid tariff discussions and NIH budget concerns, which could negatively impact long-term growth by 1%. Despite these headwinds, the company remains optimistic about long-term growth, particularly in China, cell therapy, and proteomic analytical instrumentation, while targeting operating margins above 35% within five years, and is focusing on expanding its spatial analysis platform and scaling its liquid biopsy business.

Analysis

Bio-Techne (NASDAQ:TECH), presenting at the Jefferies Global Healthcare Conference 2025, outlined a near-term outlook characterized by moderated growth and margin pressures, juxtaposed with long-term optimism. The company anticipates low single-digit overall growth in Q4 2024, with pharma growth slowing to mid-single digits from a strong double-digit performance in Q3. This moderation is attributed to tariff discussions and cautious spending by smaller biotech firms amid market uncertainties. Q4 margins are expected to contract by approximately 150 basis points, partly due to tariff impacts, following a significant 200 basis point year-over-year improvement in Q3, which saw 6% organic growth. Potential NIH budget cuts are a noted concern, estimated to potentially impact the five-year CAGR by a negative 1% in a worst-case scenario, though the company believes its core reagents business and concentration in biopharma for key growth drivers (cell therapy, proteomics, spatial analysis) will mitigate this. China, representing 8% of revenues, showed delayed recovery in Q3 but is now exhibiting subtle signs of optimism and demand recovery; Bio-Techne remains bullish on its long-term potential driven by demographic trends and advancing science, noting its core reagents were exempted from recent tariff escalations. Strategic growth pillars include cell therapy, proteomic analytical instrumentation, expansion of its spatial analysis platform (where capacity constraints have been resolved), and scaling its liquid biopsy business, which is expected to achieve profitability in a few years. Instrument revenues, approximately 10% of total, have performed strongly, particularly in protein sciences, and are considered less susceptible to capex budget fluctuations due to productivity gains. The company reiterated a long-term goal of achieving operating margins above 35% within five years and has strategies in place to mitigate tariff impacts, including inventory management and potential manufacturing shifts. Pharma growth was confirmed as genuine market growth, not a result of tariff-related pull-forwards.

Key Decisions for Investors

• Investors should weigh the company's moderated Q4 growth and margin guidance against its robust Q3 performance and clearly articulated long-term growth drivers in cell therapy, proteomics, spatial analysis, and liquid biopsy.
• Monitor developments in China's market recovery, NIH budget outcomes, and the efficacy of tariff mitigation strategies, as these are key variables influencing Bio-Techne's near-to-medium term financial performance.
• Evaluate the company's progress towards its five-year operating margin target of above 35%, considering the anticipated leverage from future growth in its key strategic areas.